The subsidiary of New Leaf Canada Inc. (NLVVF), Psirenity, has been approved to conduct its psilocybin clinical trial on depression control in Jamaica. This will go on record as the first clinical trial of this kind the company will be conducting.
The methodology which Pserinity will be using in the trial was approved by the ethics committee of the University of the West Indies. The trial will commence within the next 90 days at the Caribbean Institute for Health Research (CAIHR).
Senior Lecturer in the Department of Community Health and Psychiatry, Faculty of Medical Sciences, in the University of the West Indies, Dr. Roger Gibson will be the principal investigator in the clinical trial.
The phase one will include micro-dose study with purified psilocybin using controlled and standard release oral tablets. This entire trial is aimed at determining the safety, pharmacokinetics and tolerability of two unique psilocybin micro-dose products developed by Psirenity.
Citing industry data, it’s estimated that over 300 million people suffer from mental health issues. This suggests that the psychedelic market has a potential of over $233 billion.
